An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.
House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer genetic data under a change of ownership.
Paradromics, a brain-computer interface startup, inserted its brain implant in a person—briefly—in an early test of its technology.
The Enhanced Games, where athletes are allowed to take performance-enhancing drugs, will host its first event in May. One “enhanced” former Olympic swimmer has already broken the 50-meter freestyle record.
Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.
A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs.
Startup Colossal Biosciences has edited the DNA of a gray wolf to produce what it says is a de-extincted animal. Does that make it a true dire wolf?
In an advance for treating male infertility, researchers transplanted a patient with his own sperm-forming stem cells that were collected from testicular tissue when he was a child.
The company has partnered with Nvidia to develop “cognitive AI,” which it says will allow people with severe physical disabilities to have more natural interactions with the world around them.
The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.
